Connecticut is currently home to 1266 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New Haven, Hartford, Farmington and Stamford. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252
Recruiting
The main purpose of this study is to learn more about the safety and efficacy of investigational tirzepatide doses in participants with Type 2 diabetes and obesity that are already taking metformin. The study will last for about 89 weeks.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/23/2024
Locations: Chase Medical Research, LLC, Waterbury, Connecticut
Conditions: Type 2 Diabetes, Obesity
Register for Updates
Concurrent vs. Sequential Cessation of Dual Cigarette and E-cigarette Use
NCT06027840
Recruiting
The purpose of this research study is to understand whether concurrent treatment for cigarettes and e-cigarettes in which an individual quits both products at the same time (QUIT-C) or sequential treatment in which an individual quits cigarettes first followed by e-cigarettes is more effective for quitting both products. The study will also compare the effect of treatment on health-related biomarkers. All participants will receive varenicline, a medication used to treat tobacco use dependence, c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Cigarette Smoking, E-Cigarette Use, Smoking Cessation
Register for Updates
Open-Label Extension Study to Assess Safety, Efficacy, and Tolerability of Lorundrostat in Subjects With Uncontrolled Hypertension
NCT05968430
Recruiting
This study is to evaluate the long-term safety, efficacy and tolerability of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled hypertension.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: CMR of Greater New Haven, Hamden, Connecticut
Conditions: Hypertension
Register for Updates
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
NCT05947500
Recruiting
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor c... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Yale University, New Haven, Connecticut
Conditions: Locally Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
Register for Updates
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
NCT05933577
Recruiting
The purpose of this study is to learn if V940 which is an individualized neoantigen therapy (INT; formerly, called messenger ribonucleic acid [mRNA]-4157) with pembrolizumab (MK-3475) is safe and prevents cancer from returning in people with high-risk melanoma. Researchers want to know if V940 with pembrolizumab is better than receiving pembrolizumab alone at preventing the cancer from returning.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Yale-New Haven Hospital-Yale Cancer Center ( Site 1933), New Haven, Connecticut
Conditions: Melanoma
Register for Updates
Study of INBRX-101 Compared to Plasma-derived A1PI Therapy in Adults With AATD Emphysema
NCT05856331
Recruiting
Phase 2 study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD emphysema
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
04/23/2024
Locations: Western Connecticut Medical Group, Danbury, Connecticut
Conditions: Alpha 1-Antitrypsin Deficiency, Emphysema
Register for Updates
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI)
NCT05841030
Recruiting
The purpose of this study is to assess the socio-demographic, disease-related and treatment-related characteristics, and the standard of care (SOC) treatment patterns of participants with major depressive disorder (MDD) with anhedonia with inadequate response to their current antidepressant treatments and treated according to the standard of care treatment.
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
04/23/2024
Locations: University of Connecticut Health Center, Farmington, Connecticut
Conditions: Depressive Disorder, Major
Register for Updates
Telehealth Treatment for Opioid Use Disorders
NCT05832879
Recruiting
This study aims to use an Opioid Use Disorder (OUD) Telehealth Platform to reduce overdose events. This telehealth platform will be pilot tested to evaluate its preliminary efficacy in terms of motivating engagement in medications for OUD (MOUD), as well as its feasibility, acceptability and satisfaction to both first responders/providers and participants.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Yale School of Medicine, New Haven, Connecticut
Conditions: Opioid Use Disorder
Register for Updates
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
NCT05828069
Recruiting
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form... Read More
Gender:
All
Ages:
Between 180 days and 22 years
Trial Updated:
04/23/2024
Locations: Connecticut Children's Medical Center, Hartford, Connecticut
Conditions: Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis
Register for Updates
Avatrombopag vs. Placebo for CIT in GI Malignancies
NCT05772546
Recruiting
The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: Avatrombopag (a thrombopoietin receptor agonist) Matching placebo
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Yale New Haven Hospital, New Haven, Connecticut
Conditions: Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia
Register for Updates
A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation
NCT05757869
Recruiting
The purpose of this study is to evaluate if milvexian is at least as effective as apixaban for reducing the risk of the composite stroke and non-central nervous system (CNS) systemic embolism.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Bridgeport Hospital, Bridgeport, Connecticut
Conditions: Atrial Fibrillation
Register for Updates
A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome
NCT05754957
Recruiting
The purpose of this study is to evaluate that milvexian is superior to placebo, in addition to standard-of-care, in reducing the risk of major adverse cardiovascular event (MACE) (the composite of cardiovascular [CV] death, myocardial infarction [MI], and ischemic stroke).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/23/2024
Locations: Nuvance Health Medical Practices Cardiology Danbury, Danbury, Connecticut
Conditions: Acute Coronary Syndrome
Register for Updates